38 days ago • Posted by William Ramstein

Big pharma drug prices continue to fall from grace

While big drugmakers generate huge amounts of cash flow, it can be a challenge to grow sales and profits. Drug development is expensive and difficult and the vast majority of drugs under development fail to reach the market. Even the greatest successes eventually stop selling at high prices, either because of patent expirations or the arrival of a newer, better medication. Recently, big drug companies have had to resort to expensive biotechnology acquisitions to build their pipelines. With more and more dollars needed to move the needle, the result has been an industry rife with slow-growing top lines and valuations stuck in neutral. Sanofi, Merck, Novartis. Source: WSJ

bg_nwsletter